Nephros, Inc. (NASDAQ: NEPH) Stock Competitors & Peer Comparison
See NEPH's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Medical - Instruments & Supplies Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for NEPH and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| NEPH | $3.67 | +0.00% | 40.1M | 61.50 | $0.06 | N/A |
| ISRG | $391.95 | -2.32% | 138.5B | 40.74 | $9.62 | N/A |
| BDXA | $59.24 | -2.24% | 55.9B | 45.70 | $1.30 | +2.25% |
| BDX | $176.80 | -0.71% | 48.7B | 13.60 | $13.00 | +2.25% |
| RMD | $218.89 | -1.02% | 31.8B | 20.33 | $10.77 | +1.12% |
| MDLN | $35.61 | +1.92% | 30.1B | 26.09 | $1.36 | N/A |
| WST | $364.98 | -0.01% | 25.7B | 42.94 | $8.50 | +0.24% |
| HOLX | $76.01 | +0.00% | 17B | 31.54 | $2.41 | N/A |
| SOLV | $87.85 | +0.09% | 15.2B | 12.37 | $7.10 | N/A |
| BDXB | $48.16 | +1.39% | 13.7B | 7.60 | $6.33 | +2.25% |
Stock Comparison
Intuitive Surgical, Inc. (NASDAQ: ISRG)
NEPH vs ISRG Comparison October 2026
Nephros, Inc. (NASDAQ: NEPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPH stands at 40.1M. In comparison, ISRG has a market cap of 138.5B. Regarding current trading prices, NEPH is priced at $3.67 on the NASDAQ, while ISRG trades at $391.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPH currently has a P/E ratio of 61.50, whereas ISRG's P/E ratio is 40.74. In terms of profitability, NEPH's ROE is +0.16%, compared to ISRG's ROE of +0.18%. Regarding short-term risk, NEPH is more volatile compared to ISRG. This indicates higher risk in terms of short-term price fluctuations for NEPH.Check ISRG's competition here
Becton, Dickinson and Company (NYSE: BDXA)
NEPH vs BDXA Comparison October 2026
Nephros, Inc. (NASDAQ: NEPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPH stands at 40.1M. In comparison, BDXA has a market cap of 55.9B. Regarding current trading prices, NEPH is priced at $3.67 on the NASDAQ, while BDXA trades at $59.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPH currently has a P/E ratio of 61.50, whereas BDXA's P/E ratio is 45.70. In terms of profitability, NEPH's ROE is +0.16%, compared to BDXA's ROE of +0.04%. Regarding short-term risk, NEPH is more volatile compared to BDXA. This indicates higher risk in terms of short-term price fluctuations for NEPH.Check BDXA's competition here
Becton, Dickinson and Company (NYSE: BDX)
NEPH vs BDX Comparison October 2026
Nephros, Inc. (NASDAQ: NEPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPH stands at 40.1M. In comparison, BDX has a market cap of 48.7B. Regarding current trading prices, NEPH is priced at $3.67 on the NASDAQ, while BDX trades at $176.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPH currently has a P/E ratio of 61.50, whereas BDX's P/E ratio is 13.60. In terms of profitability, NEPH's ROE is +0.16%, compared to BDX's ROE of +0.04%. Regarding short-term risk, NEPH is more volatile compared to BDX. This indicates higher risk in terms of short-term price fluctuations for NEPH.Check BDX's competition here
ResMed Inc. (NYSE: RMD)
NEPH vs RMD Comparison October 2026
Nephros, Inc. (NASDAQ: NEPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPH stands at 40.1M. In comparison, RMD has a market cap of 31.8B. Regarding current trading prices, NEPH is priced at $3.67 on the NASDAQ, while RMD trades at $218.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPH currently has a P/E ratio of 61.50, whereas RMD's P/E ratio is 20.33. In terms of profitability, NEPH's ROE is +0.16%, compared to RMD's ROE of +0.24%. Regarding short-term risk, NEPH is more volatile compared to RMD. This indicates higher risk in terms of short-term price fluctuations for NEPH.Check RMD's competition here
Medline Inc. (NASDAQ: MDLN)
NEPH vs MDLN Comparison October 2026
Nephros, Inc. (NASDAQ: NEPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPH stands at 40.1M. In comparison, MDLN has a market cap of 30.1B. Regarding current trading prices, NEPH is priced at $3.67 on the NASDAQ, while MDLN trades at $35.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPH currently has a P/E ratio of 61.50, whereas MDLN's P/E ratio is 26.09. In terms of profitability, NEPH's ROE is +0.16%, compared to MDLN's ROE of +0.05%. Regarding short-term risk, NEPH is more volatile compared to MDLN. This indicates higher risk in terms of short-term price fluctuations for NEPH.Check MDLN's competition here
West Pharmaceutical Services, Inc. (NYSE: WST)
NEPH vs WST Comparison October 2026
Nephros, Inc. (NASDAQ: NEPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPH stands at 40.1M. In comparison, WST has a market cap of 25.7B. Regarding current trading prices, NEPH is priced at $3.67 on the NASDAQ, while WST trades at $364.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPH currently has a P/E ratio of 61.50, whereas WST's P/E ratio is 42.94. In terms of profitability, NEPH's ROE is +0.16%, compared to WST's ROE of +0.19%. Regarding short-term risk, NEPH is more volatile compared to WST. This indicates higher risk in terms of short-term price fluctuations for NEPH.Check WST's competition here
Hologic, Inc. (NASDAQ: HOLX)
NEPH vs HOLX Comparison October 2026
Nephros, Inc. (NASDAQ: NEPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPH stands at 40.1M. In comparison, HOLX has a market cap of 17B. Regarding current trading prices, NEPH is priced at $3.67 on the NASDAQ, while HOLX trades at $76.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPH currently has a P/E ratio of 61.50, whereas HOLX's P/E ratio is 31.54. In terms of profitability, NEPH's ROE is +0.16%, compared to HOLX's ROE of +0.11%. Regarding short-term risk, NEPH is more volatile compared to HOLX. This indicates higher risk in terms of short-term price fluctuations for NEPH.Check HOLX's competition here
Solventum Corporation (NYSE: SOLV)
NEPH vs SOLV Comparison October 2026
Nephros, Inc. (NASDAQ: NEPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPH stands at 40.1M. In comparison, SOLV has a market cap of 15.2B. Regarding current trading prices, NEPH is priced at $3.67 on the NASDAQ, while SOLV trades at $87.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPH currently has a P/E ratio of 61.50, whereas SOLV's P/E ratio is 12.37. In terms of profitability, NEPH's ROE is +0.16%, compared to SOLV's ROE of +0.29%. Regarding short-term risk, NEPH is more volatile compared to SOLV. This indicates higher risk in terms of short-term price fluctuations for NEPH.Check SOLV's competition here
Becton, Dickinson and Company (NYSE: BDXB)
NEPH vs BDXB Comparison October 2026
Nephros, Inc. (NASDAQ: NEPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPH stands at 40.1M. In comparison, BDXB has a market cap of 13.7B. Regarding current trading prices, NEPH is priced at $3.67 on the NASDAQ, while BDXB trades at $48.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPH currently has a P/E ratio of 61.50, whereas BDXB's P/E ratio is 7.60. In terms of profitability, NEPH's ROE is +0.16%, compared to BDXB's ROE of +0.04%. Regarding short-term risk, NEPH is more volatile compared to BDXB. This indicates higher risk in terms of short-term price fluctuations for NEPH.Check BDXB's competition here
Baxter International Inc. (NYSE: BAX)
NEPH vs BAX Comparison October 2026
Nephros, Inc. (NASDAQ: NEPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPH stands at 40.1M. In comparison, BAX has a market cap of 12.1B. Regarding current trading prices, NEPH is priced at $3.67 on the NASDAQ, while BAX trades at $23.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPH currently has a P/E ratio of 61.50, whereas BAX's P/E ratio is 11.29. In terms of profitability, NEPH's ROE is +0.16%, compared to BAX's ROE of -0.17%. Regarding short-term risk, NEPH is more volatile compared to BAX. This indicates higher risk in terms of short-term price fluctuations for NEPH.Check BAX's competition here
The Cooper Companies, Inc. (NASDAQ: COO)
NEPH vs COO Comparison October 2026
Nephros, Inc. (NASDAQ: NEPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPH stands at 40.1M. In comparison, COO has a market cap of 11.1B. Regarding current trading prices, NEPH is priced at $3.67 on the NASDAQ, while COO trades at $56.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPH currently has a P/E ratio of 61.50, whereas COO's P/E ratio is 12.48. In terms of profitability, NEPH's ROE is +0.16%, compared to COO's ROE of +0.07%. Regarding short-term risk, NEPH is more volatile compared to COO. This indicates higher risk in terms of short-term price fluctuations for NEPH.Check COO's competition here
Avantor, Inc. (NYSE: AVTR)
NEPH vs AVTR Comparison October 2026
Nephros, Inc. (NASDAQ: NEPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPH stands at 40.1M. In comparison, AVTR has a market cap of 10.4B. Regarding current trading prices, NEPH is priced at $3.67 on the NASDAQ, while AVTR trades at $15.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPH currently has a P/E ratio of 61.50, whereas AVTR's P/E ratio is 18.04. In terms of profitability, NEPH's ROE is +0.16%, compared to AVTR's ROE of -0.10%. Regarding short-term risk, NEPH is more volatile compared to AVTR. This indicates higher risk in terms of short-term price fluctuations for NEPH.Check AVTR's competition here
Repligen Corporation (NASDAQ: RGEN)
NEPH vs RGEN Comparison October 2026
Nephros, Inc. (NASDAQ: NEPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPH stands at 40.1M. In comparison, RGEN has a market cap of 10.3B. Regarding current trading prices, NEPH is priced at $3.67 on the NASDAQ, while RGEN trades at $181.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPH currently has a P/E ratio of 61.50, whereas RGEN's P/E ratio is 100.94. In terms of profitability, NEPH's ROE is +0.16%, compared to RGEN's ROE of +0.02%. Regarding short-term risk, NEPH is more volatile compared to RGEN. This indicates higher risk in terms of short-term price fluctuations for NEPH.Check RGEN's competition here
AptarGroup, Inc. (NYSE: ATR)
NEPH vs ATR Comparison October 2026
Nephros, Inc. (NASDAQ: NEPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPH stands at 40.1M. In comparison, ATR has a market cap of 7.7B. Regarding current trading prices, NEPH is priced at $3.67 on the NASDAQ, while ATR trades at $119.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPH currently has a P/E ratio of 61.50, whereas ATR's P/E ratio is 20.97. In terms of profitability, NEPH's ROE is +0.16%, compared to ATR's ROE of +0.14%. Regarding short-term risk, NEPH is more volatile compared to ATR. This indicates higher risk in terms of short-term price fluctuations for NEPH.Check ATR's competition here
Bausch + Lomb Corporation (NYSE: BLCO)
NEPH vs BLCO Comparison October 2026
Nephros, Inc. (NASDAQ: NEPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPH stands at 40.1M. In comparison, BLCO has a market cap of 6.1B. Regarding current trading prices, NEPH is priced at $3.67 on the NASDAQ, while BLCO trades at $17.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPH currently has a P/E ratio of 61.50, whereas BLCO's P/E ratio is 26.31. In terms of profitability, NEPH's ROE is +0.16%, compared to BLCO's ROE of -0.03%. Regarding short-term risk, NEPH is more volatile compared to BLCO. This indicates higher risk in terms of short-term price fluctuations for NEPH.Check BLCO's competition here
Stevanato Group S.p.A. (NYSE: STVN)
NEPH vs STVN Comparison October 2026
Nephros, Inc. (NASDAQ: NEPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPH stands at 40.1M. In comparison, STVN has a market cap of 5.5B. Regarding current trading prices, NEPH is priced at $3.67 on the NASDAQ, while STVN trades at $20.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPH currently has a P/E ratio of 61.50, whereas STVN's P/E ratio is 30.55. In terms of profitability, NEPH's ROE is +0.16%, compared to STVN's ROE of +0.09%. Regarding short-term risk, NEPH is more volatile compared to STVN. This indicates higher risk in terms of short-term price fluctuations for NEPH.Check STVN's competition here
Teleflex Incorporated (NYSE: TFX)
NEPH vs TFX Comparison October 2026
Nephros, Inc. (NASDAQ: NEPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPH stands at 40.1M. In comparison, TFX has a market cap of 5.5B. Regarding current trading prices, NEPH is priced at $3.67 on the NASDAQ, while TFX trades at $124.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPH currently has a P/E ratio of 61.50, whereas TFX's P/E ratio is 14.19. In terms of profitability, NEPH's ROE is +0.16%, compared to TFX's ROE of -0.32%. Regarding short-term risk, NEPH is more volatile compared to TFX. This indicates higher risk in terms of short-term price fluctuations for NEPH.Check TFX's competition here
Merit Medical Systems, Inc. (NASDAQ: MMSI)
NEPH vs MMSI Comparison October 2026
Nephros, Inc. (NASDAQ: NEPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPH stands at 40.1M. In comparison, MMSI has a market cap of 5.1B. Regarding current trading prices, NEPH is priced at $3.67 on the NASDAQ, while MMSI trades at $85.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPH currently has a P/E ratio of 61.50, whereas MMSI's P/E ratio is 21.83. In terms of profitability, NEPH's ROE is +0.16%, compared to MMSI's ROE of +0.09%. Regarding short-term risk, NEPH is more volatile compared to MMSI. This indicates higher risk in terms of short-term price fluctuations for NEPH.Check MMSI's competition here
ICU Medical, Inc. (NASDAQ: ICUI)
NEPH vs ICUI Comparison October 2026
Nephros, Inc. (NASDAQ: NEPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPH stands at 40.1M. In comparison, ICUI has a market cap of 4B. Regarding current trading prices, NEPH is priced at $3.67 on the NASDAQ, while ICUI trades at $159.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPH currently has a P/E ratio of 61.50, whereas ICUI's P/E ratio is 19.90. In terms of profitability, NEPH's ROE is +0.16%, compared to ICUI's ROE of +0.01%. Regarding short-term risk, NEPH is more volatile compared to ICUI. This indicates higher risk in terms of short-term price fluctuations for NEPH.Check ICUI's competition here
Envista Holdings Corp (NYSE: NVST)
NEPH vs NVST Comparison October 2026
Nephros, Inc. (NASDAQ: NEPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPH stands at 40.1M. In comparison, NVST has a market cap of 3.8B. Regarding current trading prices, NEPH is priced at $3.67 on the NASDAQ, while NVST trades at $23.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPH currently has a P/E ratio of 61.50, whereas NVST's P/E ratio is 15.96. In terms of profitability, NEPH's ROE is +0.16%, compared to NVST's ROE of +0.03%. Regarding short-term risk, NEPH is more volatile compared to NVST. This indicates higher risk in terms of short-term price fluctuations for NEPH.Check NVST's competition here
Pulse Biosciences, Inc. (NASDAQ: PLSE)
NEPH vs PLSE Comparison October 2026
Nephros, Inc. (NASDAQ: NEPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPH stands at 40.1M. In comparison, PLSE has a market cap of 3.3B. Regarding current trading prices, NEPH is priced at $3.67 on the NASDAQ, while PLSE trades at $47.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPH currently has a P/E ratio of 61.50, whereas PLSE's P/E ratio is -40.59. In terms of profitability, NEPH's ROE is +0.16%, compared to PLSE's ROE of -0.94%. Regarding short-term risk, NEPH is more volatile compared to PLSE. This indicates higher risk in terms of short-term price fluctuations for NEPH.Check PLSE's competition here
AtriCure, Inc. (NASDAQ: ATRC)
NEPH vs ATRC Comparison October 2026
Nephros, Inc. (NASDAQ: NEPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPH stands at 40.1M. In comparison, ATRC has a market cap of 2.8B. Regarding current trading prices, NEPH is priced at $3.67 on the NASDAQ, while ATRC trades at $55.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPH currently has a P/E ratio of 61.50, whereas ATRC's P/E ratio is 1712.42. In terms of profitability, NEPH's ROE is +0.16%, compared to ATRC's ROE of +0.02%. Regarding short-term risk, NEPH is more volatile compared to ATRC. This indicates higher risk in terms of short-term price fluctuations for NEPH.Check ATRC's competition here
BioLife Solutions, Inc. (NASDAQ: BLFS)
NEPH vs BLFS Comparison October 2026
Nephros, Inc. (NASDAQ: NEPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPH stands at 40.1M. In comparison, BLFS has a market cap of 1.8B. Regarding current trading prices, NEPH is priced at $3.67 on the NASDAQ, while BLFS trades at $37.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPH currently has a P/E ratio of 61.50, whereas BLFS's P/E ratio is 36.21. In terms of profitability, NEPH's ROE is +0.16%, compared to BLFS's ROE of +0.13%. Regarding short-term risk, NEPH is more volatile compared to BLFS. This indicates higher risk in terms of short-term price fluctuations for NEPH.Check BLFS's competition here
LeMaitre Vascular, Inc. (NASDAQ: LMAT)
NEPH vs LMAT Comparison October 2026
Nephros, Inc. (NASDAQ: NEPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPH stands at 40.1M. In comparison, LMAT has a market cap of 1.8B. Regarding current trading prices, NEPH is priced at $3.67 on the NASDAQ, while LMAT trades at $78.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPH currently has a P/E ratio of 61.50, whereas LMAT's P/E ratio is 29.03. In terms of profitability, NEPH's ROE is +0.16%, compared to LMAT's ROE of +0.16%. Regarding short-term risk, NEPH is more volatile compared to LMAT. This indicates higher risk in terms of short-term price fluctuations for NEPH.Check LMAT's competition here
Azenta, Inc. (NASDAQ: AZTA)
NEPH vs AZTA Comparison October 2026
Nephros, Inc. (NASDAQ: NEPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPH stands at 40.1M. In comparison, AZTA has a market cap of 1.8B. Regarding current trading prices, NEPH is priced at $3.67 on the NASDAQ, while AZTA trades at $38.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPH currently has a P/E ratio of 61.50, whereas AZTA's P/E ratio is 92.26. In terms of profitability, NEPH's ROE is +0.16%, compared to AZTA's ROE of -0.08%. Regarding short-term risk, NEPH is less volatile compared to AZTA. This indicates lower risk in terms of short-term price fluctuations for NEPH.Check AZTA's competition here
DENTSPLY SIRONA Inc. (NASDAQ: XRAY)
NEPH vs XRAY Comparison October 2026
Nephros, Inc. (NASDAQ: NEPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPH stands at 40.1M. In comparison, XRAY has a market cap of 1.7B. Regarding current trading prices, NEPH is priced at $3.67 on the NASDAQ, while XRAY trades at $8.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPH currently has a P/E ratio of 61.50, whereas XRAY's P/E ratio is 6.06. In terms of profitability, NEPH's ROE is +0.16%, compared to XRAY's ROE of -0.40%. Regarding short-term risk, NEPH is more volatile compared to XRAY. This indicates higher risk in terms of short-term price fluctuations for NEPH.Check XRAY's competition here
Kestra Medical Technologies, Ltd. (NASDAQ: KMTS)
NEPH vs KMTS Comparison October 2026
Nephros, Inc. (NASDAQ: NEPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPH stands at 40.1M. In comparison, KMTS has a market cap of 1.6B. Regarding current trading prices, NEPH is priced at $3.67 on the NASDAQ, while KMTS trades at $27.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPH currently has a P/E ratio of 61.50, whereas KMTS's P/E ratio is -10.35. In terms of profitability, NEPH's ROE is +0.16%, compared to KMTS's ROE of -0.64%. Regarding short-term risk, NEPH is more volatile compared to KMTS. This indicates higher risk in terms of short-term price fluctuations for NEPH.Check KMTS's competition here
STAAR Surgical Company (NASDAQ: STAA)
NEPH vs STAA Comparison October 2026
Nephros, Inc. (NASDAQ: NEPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPH stands at 40.1M. In comparison, STAA has a market cap of 1.1B. Regarding current trading prices, NEPH is priced at $3.67 on the NASDAQ, while STAA trades at $22.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPH currently has a P/E ratio of 61.50, whereas STAA's P/E ratio is 39.42. In terms of profitability, NEPH's ROE is +0.16%, compared to STAA's ROE of +0.01%. Regarding short-term risk, NEPH is more volatile compared to STAA. This indicates higher risk in terms of short-term price fluctuations for NEPH.Check STAA's competition here
Atrion Corporation (NASDAQ: ATRI)
NEPH vs ATRI Comparison October 2026
Nephros, Inc. (NASDAQ: NEPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPH stands at 40.1M. In comparison, ATRI has a market cap of 809.4M. Regarding current trading prices, NEPH is priced at $3.67 on the NASDAQ, while ATRI trades at $459.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPH currently has a P/E ratio of 61.50, whereas ATRI's P/E ratio is 64.50. In terms of profitability, NEPH's ROE is +0.16%, compared to ATRI's ROE of +0.08%. Regarding short-term risk, NEPH is more volatile compared to ATRI. This indicates higher risk in terms of short-term price fluctuations for NEPH.Check ATRI's competition here
AngioDynamics, Inc. (NASDAQ: ANGO)
NEPH vs ANGO Comparison October 2026
Nephros, Inc. (NASDAQ: NEPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPH stands at 40.1M. In comparison, ANGO has a market cap of 624.5M. Regarding current trading prices, NEPH is priced at $3.67 on the NASDAQ, while ANGO trades at $15.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPH currently has a P/E ratio of 61.50, whereas ANGO's P/E ratio is -38.74. In terms of profitability, NEPH's ROE is +0.16%, compared to ANGO's ROE of -0.21%. Regarding short-term risk, NEPH is more volatile compared to ANGO. This indicates higher risk in terms of short-term price fluctuations for NEPH.Check ANGO's competition here
Embecta Corp. (NASDAQ: EMBC)
NEPH vs EMBC Comparison October 2026
Nephros, Inc. (NASDAQ: NEPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPH stands at 40.1M. In comparison, EMBC has a market cap of 335.2M. Regarding current trading prices, NEPH is priced at $3.67 on the NASDAQ, while EMBC trades at $5.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPH currently has a P/E ratio of 61.50, whereas EMBC's P/E ratio is 2.17. In terms of profitability, NEPH's ROE is +0.16%, compared to EMBC's ROE of -0.14%. Regarding short-term risk, NEPH is more volatile compared to EMBC. This indicates higher risk in terms of short-term price fluctuations for NEPH.Check EMBC's competition here
Sanara MedTech Inc. (NASDAQ: SMTI)
NEPH vs SMTI Comparison October 2026
Nephros, Inc. (NASDAQ: NEPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPH stands at 40.1M. In comparison, SMTI has a market cap of 320.4M. Regarding current trading prices, NEPH is priced at $3.67 on the NASDAQ, while SMTI trades at $34.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPH currently has a P/E ratio of 61.50, whereas SMTI's P/E ratio is -580.83. In terms of profitability, NEPH's ROE is +0.16%, compared to SMTI's ROE of -4.74%. Regarding short-term risk, NEPH is more volatile compared to SMTI. This indicates higher risk in terms of short-term price fluctuations for NEPH.Check SMTI's competition here
OraSure Technologies, Inc. (NASDAQ: OSUR)
NEPH vs OSUR Comparison October 2026
Nephros, Inc. (NASDAQ: NEPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPH stands at 40.1M. In comparison, OSUR has a market cap of 273M. Regarding current trading prices, NEPH is priced at $3.67 on the NASDAQ, while OSUR trades at $3.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPH currently has a P/E ratio of 61.50, whereas OSUR's P/E ratio is -5.75. In terms of profitability, NEPH's ROE is +0.16%, compared to OSUR's ROE of -0.15%. Regarding short-term risk, NEPH is more volatile compared to OSUR. This indicates higher risk in terms of short-term price fluctuations for NEPH.Check OSUR's competition here
Anbio Biotechnology Class A Ordinary Shares (NASDAQ: NNNN)
NEPH vs NNNN Comparison October 2026
Nephros, Inc. (NASDAQ: NEPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPH stands at 40.1M. In comparison, NNNN has a market cap of 243.6M. Regarding current trading prices, NEPH is priced at $3.67 on the NASDAQ, while NNNN trades at $5.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPH currently has a P/E ratio of 61.50, whereas NNNN's P/E ratio is 37.00. In terms of profitability, NEPH's ROE is +0.16%, compared to NNNN's ROE of +0.27%. Regarding short-term risk, NEPH is less volatile compared to NNNN. This indicates lower risk in terms of short-term price fluctuations for NEPH.Check NNNN's competition here
Utah Medical Products, Inc. (NASDAQ: UTMD)
NEPH vs UTMD Comparison October 2026
Nephros, Inc. (NASDAQ: NEPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPH stands at 40.1M. In comparison, UTMD has a market cap of 236M. Regarding current trading prices, NEPH is priced at $3.67 on the NASDAQ, while UTMD trades at $74.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPH currently has a P/E ratio of 61.50, whereas UTMD's P/E ratio is 21.93. In terms of profitability, NEPH's ROE is +0.16%, compared to UTMD's ROE of +0.09%. Regarding short-term risk, NEPH is more volatile compared to UTMD. This indicates higher risk in terms of short-term price fluctuations for NEPH.Check UTMD's competition here
Pro-Dex, Inc. (NASDAQ: PDEX)
NEPH vs PDEX Comparison October 2026
Nephros, Inc. (NASDAQ: NEPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPH stands at 40.1M. In comparison, PDEX has a market cap of 204.6M. Regarding current trading prices, NEPH is priced at $3.67 on the NASDAQ, while PDEX trades at $64.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPH currently has a P/E ratio of 61.50, whereas PDEX's P/E ratio is 15.51. In terms of profitability, NEPH's ROE is +0.16%, compared to PDEX's ROE of +0.31%. Regarding short-term risk, NEPH is more volatile compared to PDEX. This indicates higher risk in terms of short-term price fluctuations for NEPH.Check PDEX's competition here
KORU Medical Systems, Inc. (NASDAQ: KRMD)
NEPH vs KRMD Comparison October 2026
Nephros, Inc. (NASDAQ: NEPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPH stands at 40.1M. In comparison, KRMD has a market cap of 136M. Regarding current trading prices, NEPH is priced at $3.67 on the NASDAQ, while KRMD trades at $2.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPH currently has a P/E ratio of 61.50, whereas KRMD's P/E ratio is -74.00. In terms of profitability, NEPH's ROE is +0.16%, compared to KRMD's ROE of -0.11%. Regarding short-term risk, NEPH is less volatile compared to KRMD. This indicates lower risk in terms of short-term price fluctuations for NEPH.Check KRMD's competition here
Stereotaxis, Inc. (AMEX: STXS)
NEPH vs STXS Comparison October 2026
Nephros, Inc. (NASDAQ: NEPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPH stands at 40.1M. In comparison, STXS has a market cap of 115.6M. Regarding current trading prices, NEPH is priced at $3.67 on the NASDAQ, while STXS trades at $1.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPH currently has a P/E ratio of 61.50, whereas STXS's P/E ratio is -6.94. In terms of profitability, NEPH's ROE is +0.16%, compared to STXS's ROE of -1.33%. Regarding short-term risk, NEPH is more volatile compared to STXS. This indicates higher risk in terms of short-term price fluctuations for NEPH.Check STXS's competition here
Akoya Biosciences, Inc. (NASDAQ: AKYA)
NEPH vs AKYA Comparison October 2026
Nephros, Inc. (NASDAQ: NEPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPH stands at 40.1M. In comparison, AKYA has a market cap of 64.4M. Regarding current trading prices, NEPH is priced at $3.67 on the NASDAQ, while AKYA trades at $1.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPH currently has a P/E ratio of 61.50, whereas AKYA's P/E ratio is -1.34. In terms of profitability, NEPH's ROE is +0.16%, compared to AKYA's ROE of -1.80%. Regarding short-term risk, NEPH is more volatile compared to AKYA. This indicates higher risk in terms of short-term price fluctuations for NEPH.Check AKYA's competition here
Daxor Corporation (NASDAQ: DXR)
NEPH vs DXR Comparison October 2026
Nephros, Inc. (NASDAQ: NEPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPH stands at 40.1M. In comparison, DXR has a market cap of 61.9M. Regarding current trading prices, NEPH is priced at $3.67 on the NASDAQ, while DXR trades at $10.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPH currently has a P/E ratio of 61.50, whereas DXR's P/E ratio is 8.63. In terms of profitability, NEPH's ROE is +0.16%, compared to DXR's ROE of +0.13%. Regarding short-term risk, NEPH is more volatile compared to DXR. This indicates higher risk in terms of short-term price fluctuations for NEPH.Check DXR's competition here
SkyAI, Inc. (NASDAQ: STSS)
NEPH vs STSS Comparison October 2026
Nephros, Inc. (NASDAQ: NEPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPH stands at 40.1M. In comparison, STSS has a market cap of 53.7M. Regarding current trading prices, NEPH is priced at $3.67 on the NASDAQ, while STSS trades at $1.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPH currently has a P/E ratio of 61.50, whereas STSS's P/E ratio is -0.02. In terms of profitability, NEPH's ROE is +0.16%, compared to STSS's ROE of -1.54%. Regarding short-term risk, NEPH is less volatile compared to STSS. This indicates lower risk in terms of short-term price fluctuations for NEPH.Check STSS's competition here
Singular Genomics Systems, Inc. (NASDAQ: OMIC)
NEPH vs OMIC Comparison October 2026
Nephros, Inc. (NASDAQ: NEPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPH stands at 40.1M. In comparison, OMIC has a market cap of 50.8M. Regarding current trading prices, NEPH is priced at $3.67 on the NASDAQ, while OMIC trades at $20.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPH currently has a P/E ratio of 61.50, whereas OMIC's P/E ratio is -0.58. In terms of profitability, NEPH's ROE is +0.16%, compared to OMIC's ROE of -0.43%. Regarding short-term risk, NEPH is more volatile compared to OMIC. This indicates higher risk in terms of short-term price fluctuations for NEPH.Check OMIC's competition here
GlucoTrack, Inc. (NASDAQ: IGAP)
NEPH vs IGAP Comparison October 2026
Nephros, Inc. (NASDAQ: NEPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPH stands at 40.1M. In comparison, IGAP has a market cap of 50.2M. Regarding current trading prices, NEPH is priced at $3.67 on the NASDAQ, while IGAP trades at $3.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPH currently has a P/E ratio of 61.50, whereas IGAP's P/E ratio is -10.52. In terms of profitability, NEPH's ROE is +0.16%, compared to IGAP's ROE of +1.80%. Regarding short-term risk, NEPH is more volatile compared to IGAP. This indicates higher risk in terms of short-term price fluctuations for NEPH.Check IGAP's competition here
Precision Optics Corporation, Inc. (NASDAQ: POCI)
NEPH vs POCI Comparison October 2026
Nephros, Inc. (NASDAQ: NEPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPH stands at 40.1M. In comparison, POCI has a market cap of 48.8M. Regarding current trading prices, NEPH is priced at $3.67 on the NASDAQ, while POCI trades at $4.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPH currently has a P/E ratio of 61.50, whereas POCI's P/E ratio is -9.70. In terms of profitability, NEPH's ROE is +0.16%, compared to POCI's ROE of -0.24%. Regarding short-term risk, NEPH is less volatile compared to POCI. This indicates lower risk in terms of short-term price fluctuations for NEPH.Check POCI's competition here
Harvard Bioscience, Inc. (NASDAQ: HBIO)
NEPH vs HBIO Comparison October 2026
Nephros, Inc. (NASDAQ: NEPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPH stands at 40.1M. In comparison, HBIO has a market cap of 36.7M. Regarding current trading prices, NEPH is priced at $3.67 on the NASDAQ, while HBIO trades at $8.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPH currently has a P/E ratio of 61.50, whereas HBIO's P/E ratio is -22.58. In terms of profitability, NEPH's ROE is +0.16%, compared to HBIO's ROE of -0.92%. Regarding short-term risk, NEPH is more volatile compared to HBIO. This indicates higher risk in terms of short-term price fluctuations for NEPH.Check HBIO's competition here
Milestone Scientific Inc. (AMEX: MLSS)
NEPH vs MLSS Comparison October 2026
Nephros, Inc. (NASDAQ: NEPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPH stands at 40.1M. In comparison, MLSS has a market cap of 33.5M. Regarding current trading prices, NEPH is priced at $3.67 on the NASDAQ, while MLSS trades at $0.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPH currently has a P/E ratio of 61.50, whereas MLSS's P/E ratio is -7.57. In terms of profitability, NEPH's ROE is +0.16%, compared to MLSS's ROE of -1.49%. Regarding short-term risk, NEPH is less volatile compared to MLSS. This indicates lower risk in terms of short-term price fluctuations for NEPH.Check MLSS's competition here
SmileDirectClub, Inc. (NASDAQ: SDC)
NEPH vs SDC Comparison October 2026
Nephros, Inc. (NASDAQ: NEPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPH stands at 40.1M. In comparison, SDC has a market cap of 29.1M. Regarding current trading prices, NEPH is priced at $3.67 on the NASDAQ, while SDC trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPH currently has a P/E ratio of 61.50, whereas SDC's P/E ratio is -0.03. In terms of profitability, NEPH's ROE is +0.16%, compared to SDC's ROE of -1.96%. Regarding short-term risk, NEPH is less volatile compared to SDC. This indicates lower risk in terms of short-term price fluctuations for NEPH.Check SDC's competition here
Invacare Corporation (NYSE: IVC)
NEPH vs IVC Comparison October 2026
Nephros, Inc. (NASDAQ: NEPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPH stands at 40.1M. In comparison, IVC has a market cap of 24.9M. Regarding current trading prices, NEPH is priced at $3.67 on the NASDAQ, while IVC trades at $0.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPH currently has a P/E ratio of 61.50, whereas IVC's P/E ratio is -0.79. In terms of profitability, NEPH's ROE is +0.16%, compared to IVC's ROE of -0.46%. Regarding short-term risk, NEPH is more volatile compared to IVC. This indicates higher risk in terms of short-term price fluctuations for NEPH.Check IVC's competition here
Retractable Technologies, Inc. (AMEX: RVP)
NEPH vs RVP Comparison October 2026
Nephros, Inc. (NASDAQ: NEPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPH stands at 40.1M. In comparison, RVP has a market cap of 21M. Regarding current trading prices, NEPH is priced at $3.67 on the NASDAQ, while RVP trades at $0.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPH currently has a P/E ratio of 61.50, whereas RVP's P/E ratio is -5.83. In terms of profitability, NEPH's ROE is +0.16%, compared to RVP's ROE of -0.05%. Regarding short-term risk, NEPH is more volatile compared to RVP. This indicates higher risk in terms of short-term price fluctuations for NEPH.Check RVP's competition here
Bionano Genomics, Inc. (NASDAQ: BNGO)
NEPH vs BNGO Comparison October 2026
Nephros, Inc. (NASDAQ: NEPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPH stands at 40.1M. In comparison, BNGO has a market cap of 17.2M. Regarding current trading prices, NEPH is priced at $3.67 on the NASDAQ, while BNGO trades at $1.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPH currently has a P/E ratio of 61.50, whereas BNGO's P/E ratio is -0.50. In terms of profitability, NEPH's ROE is +0.16%, compared to BNGO's ROE of -0.79%. Regarding short-term risk, NEPH is less volatile compared to BNGO. This indicates lower risk in terms of short-term price fluctuations for NEPH.Check BNGO's competition here
Jin Medical International Ltd. (NASDAQ: ZJYL)
NEPH vs ZJYL Comparison October 2026
Nephros, Inc. (NASDAQ: NEPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPH stands at 40.1M. In comparison, ZJYL has a market cap of 15.6M. Regarding current trading prices, NEPH is priced at $3.67 on the NASDAQ, while ZJYL trades at $1.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPH currently has a P/E ratio of 61.50, whereas ZJYL's P/E ratio is 13.61. In terms of profitability, NEPH's ROE is +0.16%, compared to ZJYL's ROE of +0.04%. Regarding short-term risk, NEPH is more volatile compared to ZJYL. This indicates higher risk in terms of short-term price fluctuations for NEPH.Check ZJYL's competition here
Regentis Biomaterials Ltd. (AMEX: RGNT)
NEPH vs RGNT Comparison October 2026
Nephros, Inc. (NASDAQ: NEPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPH stands at 40.1M. In comparison, RGNT has a market cap of 12.7M. Regarding current trading prices, NEPH is priced at $3.67 on the NASDAQ, while RGNT trades at $1.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPH currently has a P/E ratio of 61.50, whereas RGNT's P/E ratio is -0.07. In terms of profitability, NEPH's ROE is +0.16%, compared to RGNT's ROE of N/A. Regarding short-term risk, NEPH is more volatile compared to RGNT. This indicates higher risk in terms of short-term price fluctuations for NEPH.Check RGNT's competition here
Cuprina Holdings (Cayman) Limited Class A Ordinary Shares (NASDAQ: CUPR)
NEPH vs CUPR Comparison October 2026
Nephros, Inc. (NASDAQ: NEPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPH stands at 40.1M. In comparison, CUPR has a market cap of 6.5M. Regarding current trading prices, NEPH is priced at $3.67 on the NASDAQ, while CUPR trades at $2.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPH currently has a P/E ratio of 61.50, whereas CUPR's P/E ratio is -1.75. In terms of profitability, NEPH's ROE is +0.16%, compared to CUPR's ROE of -15.69%. Regarding short-term risk, NEPH is less volatile compared to CUPR. This indicates lower risk in terms of short-term price fluctuations for NEPH.Check CUPR's competition here
Femasys Inc. (NASDAQ: FEMY)
NEPH vs FEMY Comparison October 2026
Nephros, Inc. (NASDAQ: NEPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPH stands at 40.1M. In comparison, FEMY has a market cap of 6.3M. Regarding current trading prices, NEPH is priced at $3.67 on the NASDAQ, while FEMY trades at $2.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPH currently has a P/E ratio of 61.50, whereas FEMY's P/E ratio is -0.46. In terms of profitability, NEPH's ROE is +0.16%, compared to FEMY's ROE of -2.26%. Regarding short-term risk, NEPH is less volatile compared to FEMY. This indicates lower risk in terms of short-term price fluctuations for NEPH.Check FEMY's competition here
Lucyd, Inc (NASDAQ: LUCY)
NEPH vs LUCY Comparison October 2026
Nephros, Inc. (NASDAQ: NEPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPH stands at 40.1M. In comparison, LUCY has a market cap of 5.6M. Regarding current trading prices, NEPH is priced at $3.67 on the NASDAQ, while LUCY trades at $0.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPH currently has a P/E ratio of 61.50, whereas LUCY's P/E ratio is -0.69. In terms of profitability, NEPH's ROE is +0.16%, compared to LUCY's ROE of -0.89%. Regarding short-term risk, NEPH is more volatile compared to LUCY. This indicates higher risk in terms of short-term price fluctuations for NEPH.Check LUCY's competition here
NanoString Technologies, Inc. (NASDAQ: NSTG)
NEPH vs NSTG Comparison October 2026
Nephros, Inc. (NASDAQ: NEPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPH stands at 40.1M. In comparison, NSTG has a market cap of 5.1M. Regarding current trading prices, NEPH is priced at $3.67 on the NASDAQ, while NSTG trades at $0.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPH currently has a P/E ratio of 61.50, whereas NSTG's P/E ratio is -0.03. In terms of profitability, NEPH's ROE is +0.16%, compared to NSTG's ROE of -1.43%. Regarding short-term risk, NEPH is less volatile compared to NSTG. This indicates lower risk in terms of short-term price fluctuations for NEPH.Check NSTG's competition here
Predictive Oncology Inc. (NASDAQ: POAI)
NEPH vs POAI Comparison October 2026
Nephros, Inc. (NASDAQ: NEPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPH stands at 40.1M. In comparison, POAI has a market cap of 3.6M. Regarding current trading prices, NEPH is priced at $3.67 on the NASDAQ, while POAI trades at $4.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPH currently has a P/E ratio of 61.50, whereas POAI's P/E ratio is -0.38. In terms of profitability, NEPH's ROE is +0.16%, compared to POAI's ROE of -21.19%. Regarding short-term risk, NEPH is less volatile compared to POAI. This indicates lower risk in terms of short-term price fluctuations for NEPH.Check POAI's competition here
Meihua International Medical Technologies Co., Ltd. (NASDAQ: MHUA)
NEPH vs MHUA Comparison October 2026
Nephros, Inc. (NASDAQ: NEPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPH stands at 40.1M. In comparison, MHUA has a market cap of 2.4M. Regarding current trading prices, NEPH is priced at $3.67 on the NASDAQ, while MHUA trades at $7.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPH currently has a P/E ratio of 61.50, whereas MHUA's P/E ratio is 0.25. In terms of profitability, NEPH's ROE is +0.16%, compared to MHUA's ROE of +0.07%. Regarding short-term risk, NEPH is more volatile compared to MHUA. This indicates higher risk in terms of short-term price fluctuations for NEPH.Check MHUA's competition here
G Medical Innovations Holdings Ltd (NASDAQ: GMVD)
NEPH vs GMVD Comparison October 2026
Nephros, Inc. (NASDAQ: NEPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPH stands at 40.1M. In comparison, GMVD has a market cap of 1.8M. Regarding current trading prices, NEPH is priced at $3.67 on the NASDAQ, while GMVD trades at $0.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPH currently has a P/E ratio of 61.50, whereas GMVD's P/E ratio is -0.01. In terms of profitability, NEPH's ROE is +0.16%, compared to GMVD's ROE of +2.09%. Regarding short-term risk, NEPH is less volatile compared to GMVD. This indicates lower risk in terms of short-term price fluctuations for NEPH.Check GMVD's competition here
G Medical Innovations Holdings Ltd (NASDAQ: GMVDW)
NEPH vs GMVDW Comparison October 2026
Nephros, Inc. (NASDAQ: NEPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPH stands at 40.1M. In comparison, GMVDW has a market cap of 1.8M. Regarding current trading prices, NEPH is priced at $3.67 on the NASDAQ, while GMVDW trades at $7.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPH currently has a P/E ratio of 61.50, whereas GMVDW's P/E ratio is N/A. In terms of profitability, NEPH's ROE is +0.16%, compared to GMVDW's ROE of +2.09%. Regarding short-term risk, NEPH is less volatile compared to GMVDW. This indicates lower risk in terms of short-term price fluctuations for NEPH.Check GMVDW's competition here
Avinger, Inc. (NASDAQ: AVGR)
NEPH vs AVGR Comparison October 2026
Nephros, Inc. (NASDAQ: NEPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPH stands at 40.1M. In comparison, AVGR has a market cap of 1.5M. Regarding current trading prices, NEPH is priced at $3.67 on the NASDAQ, while AVGR trades at $0.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPH currently has a P/E ratio of 61.50, whereas AVGR's P/E ratio is -0.05. In terms of profitability, NEPH's ROE is +0.16%, compared to AVGR's ROE of +17.82%. Regarding short-term risk, NEPH is less volatile compared to AVGR. This indicates lower risk in terms of short-term price fluctuations for NEPH.Check AVGR's competition here
NEXGEL, Inc. (NASDAQ: NXGL)
NEPH vs NXGL Comparison October 2026
Nephros, Inc. (NASDAQ: NEPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPH stands at 40.1M. In comparison, NXGL has a market cap of 1.5M. Regarding current trading prices, NEPH is priced at $3.67 on the NASDAQ, while NXGL trades at $0.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPH currently has a P/E ratio of 61.50, whereas NXGL's P/E ratio is -0.25. In terms of profitability, NEPH's ROE is +0.16%, compared to NXGL's ROE of -1.33%. Regarding short-term risk, NEPH is more volatile compared to NXGL. This indicates higher risk in terms of short-term price fluctuations for NEPH.Check NXGL's competition here
NEXGEL, Inc. (NASDAQ: NXGLW)
NEPH vs NXGLW Comparison October 2026
Nephros, Inc. (NASDAQ: NEPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPH stands at 40.1M. In comparison, NXGLW has a market cap of 1.1M. Regarding current trading prices, NEPH is priced at $3.67 on the NASDAQ, while NXGLW trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPH currently has a P/E ratio of 61.50, whereas NXGLW's P/E ratio is -0.02. In terms of profitability, NEPH's ROE is +0.16%, compared to NXGLW's ROE of -1.33%. Regarding short-term risk, NEPH is more volatile compared to NXGLW. This indicates higher risk in terms of short-term price fluctuations for NEPH.Check NXGLW's competition here
Lucyd, Inc (NASDAQ: LUCYW)
NEPH vs LUCYW Comparison October 2026
Nephros, Inc. (NASDAQ: NEPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPH stands at 40.1M. In comparison, LUCYW has a market cap of 296.1K. Regarding current trading prices, NEPH is priced at $3.67 on the NASDAQ, while LUCYW trades at $0.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPH currently has a P/E ratio of 61.50, whereas LUCYW's P/E ratio is N/A. In terms of profitability, NEPH's ROE is +0.16%, compared to LUCYW's ROE of -0.89%. Regarding short-term risk, NEPH is less volatile compared to LUCYW. This indicates lower risk in terms of short-term price fluctuations for NEPH.Check LUCYW's competition here
Apria, Inc. (NASDAQ: APR)
NEPH vs APR Comparison October 2026
Nephros, Inc. (NASDAQ: NEPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPH stands at 40.1M. In comparison, APR has a market cap of 0. Regarding current trading prices, NEPH is priced at $3.67 on the NASDAQ, while APR trades at $37.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPH currently has a P/E ratio of 61.50, whereas APR's P/E ratio is 22.59. In terms of profitability, NEPH's ROE is +0.16%, compared to APR's ROE of +9.81%. Regarding short-term risk, NEPH is more volatile compared to APR. This indicates higher risk in terms of short-term price fluctuations for NEPH.Check APR's competition here
IntriCon Corporation (NASDAQ: IIN)
NEPH vs IIN Comparison October 2026
Nephros, Inc. (NASDAQ: NEPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPH stands at 40.1M. In comparison, IIN has a market cap of 0. Regarding current trading prices, NEPH is priced at $3.67 on the NASDAQ, while IIN trades at $24.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPH currently has a P/E ratio of 61.50, whereas IIN's P/E ratio is 226.45. In terms of profitability, NEPH's ROE is +0.16%, compared to IIN's ROE of -0.00%. Regarding short-term risk, NEPH is more volatile compared to IIN. This indicates higher risk in terms of short-term price fluctuations for NEPH.Check IIN's competition here
Hill-Rom Holdings, Inc. (NYSE: HRC)
NEPH vs HRC Comparison October 2026
Nephros, Inc. (NASDAQ: NEPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPH stands at 40.1M. In comparison, HRC has a market cap of 0. Regarding current trading prices, NEPH is priced at $3.67 on the NASDAQ, while HRC trades at $155.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPH currently has a P/E ratio of 61.50, whereas HRC's P/E ratio is 41.92. In terms of profitability, NEPH's ROE is +0.16%, compared to HRC's ROE of +0.14%. Regarding short-term risk, NEPH is more volatile compared to HRC. This indicates higher risk in terms of short-term price fluctuations for NEPH.Check HRC's competition here
Analogic Corporation (NASDAQ: ALOG)
NEPH vs ALOG Comparison October 2026
Nephros, Inc. (NASDAQ: NEPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPH stands at 40.1M. In comparison, ALOG has a market cap of 0. Regarding current trading prices, NEPH is priced at $3.67 on the NASDAQ, while ALOG trades at $83.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPH currently has a P/E ratio of 61.50, whereas ALOG's P/E ratio is 40.93. In terms of profitability, NEPH's ROE is +0.16%, compared to ALOG's ROE of -0.15%. Regarding short-term risk, NEPH is more volatile compared to ALOG. This indicates higher risk in terms of short-term price fluctuations for NEPH.Check ALOG's competition here
Antares Pharma, Inc. (NASDAQ: ATRS)
NEPH vs ATRS Comparison October 2026
Nephros, Inc. (NASDAQ: NEPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPH stands at 40.1M. In comparison, ATRS has a market cap of 0. Regarding current trading prices, NEPH is priced at $3.67 on the NASDAQ, while ATRS trades at $5.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPH currently has a P/E ratio of 61.50, whereas ATRS's P/E ratio is 14.95. In terms of profitability, NEPH's ROE is +0.16%, compared to ATRS's ROE of +0.31%. Regarding short-term risk, NEPH is more volatile compared to ATRS. This indicates higher risk in terms of short-term price fluctuations for NEPH.Check ATRS's competition here
Invuity, Inc. (NASDAQ: IVTY)
NEPH vs IVTY Comparison October 2026
Nephros, Inc. (NASDAQ: NEPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPH stands at 40.1M. In comparison, IVTY has a market cap of 0. Regarding current trading prices, NEPH is priced at $3.67 on the NASDAQ, while IVTY trades at $7.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPH currently has a P/E ratio of 61.50, whereas IVTY's P/E ratio is -3.80. In terms of profitability, NEPH's ROE is +0.16%, compared to IVTY's ROE of -2.40%. Regarding short-term risk, NEPH is more volatile compared to IVTY. This indicates higher risk in terms of short-term price fluctuations for NEPH.Check IVTY's competition here